Health systems have spent the past few years asking whether patients will engage with digital care. Can they activate the portal, respond to the reminder, complete the symptom survey, join the virtual visit, or use the AI driven support tool? Those questions matter, but they are no longer enough. The next hidden failure point in digital health is tolerability. A tool can be available, clinically relevant, and even integrated into operations, yet still ask too much of the person using it.
Tolerability in digital health is more than a subjective experience; it is a measurable clinical parameter. It represents the patient’s ability to process and sustain an intervention without prohibitive cognitive strain, sensory overload, or practical fatigue. This burden can be quantified using validated psychometric instruments such as the NASA Task Load Index (NASA-TLX) to assess mental demand, or the User Burden Scale (UBS) to capture the multidimensional costs of digital participation. It becomes especially important in recovery and survivorship care, where patients are often expected to manage complex information at the exact moment their ability to do so may be weakest.
The National Cancer Institute notes that cancer survivors report more symptoms of cognitive impairment than people without a history of cancer, including memory problems, reduced concentration, slower information processing, and reduced executive function. Those symptoms are also tied to difficulty functioning in daily life and at work.
That is why engagement metrics can be misleading. The American Cancer Society estimates that 18.6 million people in the United States were living with a history of cancer as of January 1, 2025, and projects that number to exceed 22 million by 2035. If health systems continue to layer portals, symptom trackers, remote monitoring, patient reported outcome tools, AI navigation, and digital follow up onto this population, they need a more mature question than whether the tool was offered. They need to ask whether patients can actually use these tools well while coping with fatigue, stress, disrupted sleep, and reduced mental stamina.
A recent patient driven scoping review in JMIR Cancer points to the problem clearly. It found that digital health portals for people living with or beyond cancer are increasingly common, but their impact on clinical outcomes remains uncertain and equity related factors such as digital proficiency, access, and health literacy remain insufficiently evaluated. That is not a minor implementation detail. It suggests that healthcare is still more comfortable measuring access to digital tools than measuring whether patients can tolerate and benefit from them in the real world.
The same pattern appears across digital care more broadly. A npj Digital Medicine systematic review found that outcomes from device based monitoring depend not only on the technology itself, but on patient support, clinical integration, and sustained engagement. In other words, digital tools do not succeed in isolation. They succeed when the care pathway around them reduces burden rather than adding to it. Yet healthcare still too often treats activation as proof of readiness. Patients are onboarded, nudged, reminded, and monitored, while the system rarely asks whether the accumulating workload of participation is quietly undermining recovery.
Dementia and caregiving make the tolerability problem even harder to ignore. Digital support may appear scalable on paper, but cognitive change, caregiver mediation, and emotional strain can transform even a well designed tool into one more layer of work. If a patient cannot reliably interpret prompts, if repeated messaging increases anxiety, or if the caregiver must absorb the operational burden of keeping the patient “engaged,” the intervention may be succeeding technically while failing clinically. That is the kind of gap healthcare still struggles to see, because standard digital metrics rarely capture spillover burden or human tolerance.
Clinicians are already showing us what happens when digital systems ignore human limits. A npj Digital Medicine study found that both EHR data usability and system usability shape physicians’ cognitive load. A scoping review in BMC Nursing described alarm fatigue as a significant risk to both patient safety and healthcare worker well being, driven by repeated exposure to non actionable signals, sensory overload, emotional strain, and desensitization. AHRQ is now explicitly funding work on artificial intelligence and human factors in healthcare quality and safety because cognitive load, communication challenges, and system usability are still central to safe implementation. If trained clinicians in structured environments can be overloaded by poorly governed digital systems, patients managing recovery at home under fatigue and uncertainty are even more vulnerable to dropout, confusion, and silent nonuse. This vulnerability highlights a critical shift in the nature of clinical harm: we are entering an era of digital iatrogenesis. In this context, patient injury is not caused by pharmacological errors or surgical complications, but by flawed interfaces that induce cognitive collapse or drive clinical non-adherence. For regulators and health systems, recognizing the digital interface as a potential vector for iatrogenic harm is no longer a design preference – it is a safety imperative.
This is where digital health needs a tolerability layer. Every digital recovery tool should be evaluated not only for activation and adherence, but for cognitive demand, sensory demand, emotional load, and caregiver spillover. Health systems should know how often a patient abandons a task halfway through, whether frequent reminders create stress rather than support, whether symptom tracking itself increases anxiety, and whether the caregiver is quietly doing the work required to keep the patient “engaged.” In immersive and interactive tools, the issue becomes even more visible. Research on virtual and augmented reality interventions has shown that adverse effects are inconsistently reported, even when symptoms such as cybersickness are documented. That is a warning for digital health more broadly. Tolerability is not a side note. It is part of whether an intervention is safe and usable as care.
Healthcare already knows how to build safety and efficacy frameworks for drugs, devices, and procedures. Digital health now needs the same seriousness about human tolerance. Some patients need fewer prompts, slower pacing, simpler interfaces, and clearer escalation pathways. Some survivors need recovery support that accounts for reduced attention and cognitive fatigue rather than assuming they can behave like fully restored users. Some caregivers need relief, not one more dashboard. Engagement still matters. But the more important question is whether the intervention respects the human nervous system of the person on the receiving end. Until health systems start measuring tolerability alongside engagement, many digital tools will continue to look successful on paper while quietly failing the people they were supposed to help.
Photo: kieferpix, Getty Images
Nargiz Noimann is a neuroscientist afounder focused on how immersive technology and AI can support cognitive resilience and emotional recovery in clinical and post treatment settings. She has more than 25 years of international experience across neuroscience, psychotechnology, and healthcare innovation, and has studied at institutions including Stanford University. Nargiz is the founder of X Technology, a UAE based healthtech company developing AI powered VR programs designed to support recovery experiences for patients and caregivers. She also leads the Scientific Research Center for Psychotechnologies in Kazakhstan, where her work explores structured approaches to mental resilience, attention, and recovery in high stress and chronic illness contexts.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
